Literature DB >> 15911448

Development and evaluation of serological assays for detection of human hantavirus infections caused by Sin Nombre virus.

Jonas Schmidt1, Helga Meisel, Brian Hjelle, Detlev H Krüger, Rainer Ulrich.   

Abstract

BACKGROUND: The hantavirus cardiopulmonary syndrome (HCPS) was first recognized in 1993 after a cluster of acute respiratory distress syndrome deaths in the southwestern of the United States. The major causative agent of HCPS in North America is the Sin Nombre virus (SNV) carried by the deer mouse Peromyscus maniculatus. The first HCPS case imported to Europe was reported in 2002.
OBJECTIVES: The objective of the study was to develop and evaluate ELISA and Western blot tests for the serological detection of human infections caused by SNV including those imported to Europe. STUDY
DESIGN: A polyhistidine (His)-tagged recombinant nucleocapsid (rN) protein of SNV was expressed in Saccharomyces cerevisiae and purified by nickel chelation chromatography. On the basis of the purified SNV rN protein mu-capture and indirect IgM and IgG ELISAs and an IgG Western blot were developed. The evaluation of the tests was performed using a negative serum panel and a blinded serum panel from the US containing acute-phase sera from HCPS patients.
RESULTS: Based upon the results obtained using a panel of negative control sera the specificity for SNV mu-capture and indirect IgM and IgG ELISAs were found to be 100%. All 33 sera from SNV-infected HCPS patients included in the blinded panel were detected by the SNV mu-capture and indirect IgM ELISAs. Twenty-nine out of the 33 SNV-IgM positive sera reacted also in the SNV-IgG ELISA. An SNV-IgG Western blot confirmed the data of the SNV-IgG ELISA. Although the majority of anti-SNV positive sera cross-reacted with rN proteins of Puumala virus and Dobrava virus, the lacking reactivity of a few sera with these heterologous rN antigens in the corresponding IgM and IgG ELISAs demonstrates the value of virus-specific test formats for acute-phase sera.
CONCLUSIONS: The novel SNV ELISA and Western blot tests represent a useful tool for the serological detection of SNV infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15911448     DOI: 10.1016/j.jcv.2005.01.003

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  11 in total

1.  Truncated hantavirus nucleocapsid proteins for serotyping Sin Nombre, Andes, and Laguna Negra hantavirus infections in humans and rodents.

Authors:  Takaaki Koma; Kumiko Yoshimatsu; Noemi Pini; David Safronetz; Midori Taruishi; Silvana Levis; Rika Endo; Kenta Shimizu; Shumpei P Yasuda; Hideki Ebihara; Heinz Feldmann; Delia Enria; Jiro Arikawa
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

2.  Seroprevalence study in forestry workers of a non-endemic region in eastern Germany reveals infections by Tula and Dobrava-Belgrade hantaviruses.

Authors:  Marc Mertens; Jörg Hofmann; Rasa Petraityte-Burneikiene; Mario Ziller; Kestutis Sasnauskas; Robert Friedrich; Olaf Niederstrasser; Detlev H Krüger; Martin H Groschup; Eckhardt Petri; Sandra Werdermann; Rainer G Ulrich
Journal:  Med Microbiol Immunol       Date:  2011-05-25       Impact factor: 3.402

3.  Development of novel immunoglobulin G (IgG), IgA, and IgM enzyme immunoassays based on recombinant Puumala and Dobrava hantavirus nucleocapsid proteins.

Authors:  Helga Meisel; Anne Wolbert; Ausra Razanskiene; Andreas Marg; Andris Kazaks; Kestutis Sasnauskas; Georg Pauli; Rainer Ulrich; Detlev H Krüger
Journal:  Clin Vaccine Immunol       Date:  2006-10-04

4.  Utilization of hantavirus antibody results generated over a five-year period to develop an improved serologic algorithm for detecting acute Sin Nombre hantavirus infection.

Authors:  Harry E Prince; Xin Su; Wayne R Hogrefe
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

5.  Impact of the Yosemite hantavirus outbreak on hantavirus antibody testing at a national reference laboratory.

Authors:  Harry E Prince; Jay M Lieberman
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

6.  Phylogenetic analysis of Puumala virus subtype Bavaria, characterization and diagnostic use of its recombinant nucleocapsid protein.

Authors:  Marc Mertens; Eveline Kindler; Petra Emmerich; Jutta Esser; Christiane Wagner-Wiening; Roman Wölfel; Rasa Petraityte-Burneikiene; Jonas Schmidt-Chanasit; Aurelija Zvirbliene; Martin H Groschup; Gerhard Dobler; Martin Pfeffer; Gerald Heckel; Rainer G Ulrich; Sandra S Essbauer
Journal:  Virus Genes       Date:  2011-05-20       Impact factor: 2.332

7.  A new Puumala hantavirus subtype in rodents associated with an outbreak of Nephropathia epidemica in South-East Germany in 2004.

Authors:  S Essbauer; J Schmidt; F J Conraths; R Friedrich; J Koch; W Hautmann; M Pfeffer; R Wölfel; J Finke; G Dobler; R Ulrich
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

8.  Seroepidemiological study in a Puumala virus outbreak area in South-East Germany.

Authors:  Marc Mertens; Roman Wölfel; Katrin Ullrich; Kumiko Yoshimatsu; Jana Blumhardt; Ina Römer; Jutta Esser; Jonas Schmidt-Chanasit; Martin H Groschup; Gerhard Dobler; Sandra S Essbauer; Rainer G Ulrich
Journal:  Med Microbiol Immunol       Date:  2009-01-16       Impact factor: 3.402

9.  Indirect immunofluorescence assay for the simultaneous detection of antibodies against clinically important old and new world hantaviruses.

Authors:  Sabine Lederer; Erik Lattwein; Merle Hanke; Karen Sonnenberg; Winfried Stoecker; Åke Lundkvist; Antti Vaheri; Olli Vapalahti; Paul K S Chan; Heinz Feldmann; Daryl Dick; Jonas Schmidt-Chanasit; Paula Padula; Pablo A Vial; Raluca Panculescu-Gatej; Cornelia Ceianu; Paul Heyman; Tatjana Avšič-Županc; Matthias Niedrig
Journal:  PLoS Negl Trop Dis       Date:  2013-04-04

Review 10.  Viral hemorrhagic fevers: current status of endemic disease and strategies for control.

Authors:  Dennis J Cleri; Anthony J Ricketti; Richard B Porwancher; Luz S Ramos-Bonner; John R Vernaleo
Journal:  Infect Dis Clin North Am       Date:  2006-06       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.